- Home
- SMTK vs RNAZ Comparison
SMTK vs RNAZ Comparison
Compare SMTK & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- RNAZ
- Stock Information
- Founded
- SMTK 2009
- RNAZ 2016
- Country
- SMTK United Kingdom
- RNAZ United States
- Employees
- SMTK N/A
- RNAZ N/A
- Industry
- SMTK
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- SMTK
- RNAZ Health Care
- Exchange
- SMTK NYSE
- RNAZ Nasdaq
- Market Cap
- SMTK 6.1M
- RNAZ 6.1M
- IPO Year
- SMTK N/A
- RNAZ 2021
- Fundamental
- Price
- SMTK $0.97
- RNAZ $8.69
- Analyst Decision
- SMTK
- RNAZ Strong Buy
- Analyst Count
- SMTK 0
- RNAZ 1
- Target Price
- SMTK N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- SMTK 192.5K
- RNAZ 27.7K
- Earning Date
- SMTK 08-11-2025
- RNAZ 08-13-2025
- Dividend Yield
- SMTK N/A
- RNAZ N/A
- EPS Growth
- SMTK N/A
- RNAZ N/A
- EPS
- SMTK N/A
- RNAZ N/A
- Revenue
- SMTK $105,000.00
- RNAZ N/A
- Revenue This Year
- SMTK N/A
- RNAZ N/A
- Revenue Next Year
- SMTK N/A
- RNAZ N/A
- P/E Ratio
- SMTK N/A
- RNAZ N/A
- Revenue Growth
- SMTK 854.54
- RNAZ N/A
- 52 Week Low
- SMTK $0.78
- RNAZ $6.15
- 52 Week High
- SMTK $7.80
- RNAZ $905.52
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- RNAZ 52.45
- Support Level
- SMTK N/A
- RNAZ $8.04
- Resistance Level
- SMTK N/A
- RNAZ $9.70
- Average True Range (ATR)
- SMTK 0.00
- RNAZ 0.64
- MACD
- SMTK 0.00
- RNAZ 0.29
- Stochastic Oscillator
- SMTK 0.00
- RNAZ 57.26
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in several applications, including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.